Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Stifel

<< Previous

Bullboard Posts

Comment by Daudau11on Nov 12, 2024 5:01pm

46 Views

Post# 36309012

RE:RE:Stifel

Tbh, I don't see any stocks I own doing well lately. The only things that are going up nowadays are, Tech/AI and Crypto. Thats like it. Seems like the the market believes thats all we need in the future Tech/AI & Cyrpto. Everything else is worthless.

<< Previous

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale